Intravenous, non-viral RNAi gene therapy of brain cancer

Expert Opinion on Biological Therapy

Volumn 4, Issue 7, 2004, Pages 1103-1113

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Epidermal growth factor receptor; Insulin receptor; Liposomes; Transferrin receptor

Indexed keywords

BETA GALACTOSIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; GEFITINIB; HUMAN INSULIN RECEPTOR ANTIBODY; IMMUNOLIPOSOME; INSULIN RECEPTOR; LUCIFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 83 14; MONOCLONAL ANTIBODY 8D3; MONOCLONAL ANTIBODY OX26; PEGYLATED IMMUNOLIPOSOME; PLASMID DNA; RNA; SHORT HAIRPIN RNA; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN CANCER; CANCER IMMUNOTHERAPY; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG CARRIERS; FEASIBILITY STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENES, REPORTER; GLIOMA; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LUCIFERASES; MACACA MULATTA; MICE; MICE, SCID; NEOPLASM PROTEINS; ONCOGENES; POLYETHYLENE GLYCOLS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, INSULIN; RECEPTORS, TRANSFERRIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3142731321     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.7.1103     Document Type: Review

References (44)

1. NIIDOME T, OHMORI N, ICHINOSE A et al.: Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells. J. Biol. Chem. (1997) 272(24):15307-15312.
2. MAHATO RI, ROLLAND A, TOMLINSON E: Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharm. Res. (1997) 14(7):853-859.
3. PLANK C, TANG MX, WOLFE AR, SZOKA FC JR: Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum. Gene Ther. (1999) 10(2):319-332.
4. HOFLAND HE, NAGY D, LIU JJ et al.: In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharm. Res. (1997) 14(6):742-749.
5. ISACSON R, KULL B, SALMI P, WAHLESTEDT C: Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain. Acta Physiol. Scand. (2003) 179(2):173-177.
6. HUTVAGNER G, ZAMORE PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science (2002) 297(5589):2056-2060.
7. DYKXHOORN DM, NOVINA CD, SHARP PA: Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. (2003) 4(6):457-467.
8. CHIRMULE N, PROPERT K, MAGOSIN S et al.: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. (1999) 6(9):1574-1583.
9. WU X, LI Y, CRISE B, BURGESS SM: Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 300(5626):1749-1751.
10. NAKAI H, MONTINI E, FUESS S et al.: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. (2003) 34(3):297-302.
11. 33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. J. Pharm. Sci. (1996) 85(6):612-618.
12. RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. (1997) 3(12):1354-1361. This study shows limitations in transcranial delivery of genes to brain cancer.
13. PARDRIDGE WM: Drug and gene delivery to the brain: the vascular route. Neuron (2002) 36(4):555-558.
14. FIDLER IJ, YANO S, ZHANG RD, FUJIMAKI T, BUCANA CD: The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. (2002) 3(1):53-57.
15. ZHANG Y, ZHU C, PARDRIDGE WM: Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. (2002) 6(1):67-72.
16. PARDRIDGE WM: Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. (2002) 1(2):131-139.
17. PARDRIDGE WM, EISENBERG J, YANG J: Human blood-brain barrier insulin receptor. J. Neurochem. (1985) 44(6):1771-1778.
18. PARDRIDGE WM: Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press, Cambridge, UK (2001):209.
19. SHAH N, ZHANG S, HARADA S, SMITH RM, JARETT L: Electron microscopic visualization of insulin translocation into the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin. Endocrinology (1995) 136(7):2825-2835. This study shows that the insulin receptor normally serves to deliver its endogenous ligand, insulin, to the nuclear compartment following uptake from the extracellular space.
20. PARDRIDGE WM, KANG YS, BUCIAK JL, YANG J: Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. (1995) 12(6):807-816.
21. BICKEL U, KANG YS, YOSHIKAWA T, PARDRIDGE WM: In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J. Histochem. Cytochem. (1994) 42(11):1493-1497. Electron microscopic evidence for receptor-mediated transcytosis of peptidomimetic mAb across the BBB.
22. PAPAHADJOPOULOS D, ALLEN TM, GABIZON A et al.: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA (1991) 88(24):11460-11464. The initial description of stealth liposomes with improved plasma pharmacokinetics.
23. HUWYLER J, WU D, PARDRIDGE WM: Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA (1996) 93(24):14164-14169. The first demonstration of receptor-mediated transport of PILs across the BBB.
24. ZHANG Y, BOADO RJ, PARDRIDGE WM: In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. (2003) 5(12):1039-1045. The first study of RNAi in the brain in vivo following intravenous administration of the shRNA-encoding plasmid.
25. ZHANG Y, BRYANT J, ZHANG YF, CHARLES A, BOADO RJ, PARDRIDGE WM: Intravenous RNAi gene therapy targeting the human EGF receptor prolongs survival in intra-cranial brain cancer. Clin. Cancer Res. (2004) 10(11):3667-3677. The first study of prolongation of survival in cancer with RNAi-based gene therapy.
26. LEE HJ, ENGELHARDT B, LESLEY J, BICKEL U, PARDRIDGE WM: Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. (2000) 292(3):1048-1052.
27. ZHANG Y, JEONG LEE H, BOADO RJ, PARDRIDGE WM: Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. (2002) 4(2):183-194. This study shows plasmid DNA is largely confined to the nuclear compartment following delivery to cells with PILs.
28. SHI N, PARDRIDGE WM: Non-invasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA (2000) 97:7567-7572.
29. TAM P, MONCK M, LEE D et al.: Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. (2000) 7(21):1867-1874.
30. ZHANG Y, CALON F, ZHU C, BOADO RJ, PARDRIDGE WM: Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. (2003) 14(1):1-12.
31. CORNELIS S, VANDENBRANDEN M, RUYSSCHAERT JM, ELOUAHABI A: Role of intracellular cationic liposome-DNA complex dissociation in transfection mediated by cationic lipids. DNA Cell Biol. (2002) 21(2):91-97. This study shows that plasmid DNA is largely confined to the cytoplasmic compartment following delivery to cells with cationic liposome.
32. ZHANG Y, SCHLACHETZKI F, PARDRIDGE WM: Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. (2003) 7(1):11-18. Global expression of transgene in brain of adult rhesus monkey is demonstrated following intravenous administration of gene encapsulated in PILs.
33. SHI N, BOADO RJ, PARDRIDGE WM: Receptor-mediated gene targeting to tissues in the rat in vivo. Pharm. Res. (2001) 18:1091-1095.
34. SHI N, ZHANG Y, ZHU C, BOADO RJ, PARDRIDGE WM: Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA (2001) 98(22):12754-12759. Expression of exogenous gene in the mouse is confined to the brain with combined use of brain-specific gene promoter and PIL gene transfer technology.
35. ZHANG Y, SCHLACHETZKI F, LI JY, BOADO RJ, PARDRIDGE WM: Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. (2003) 9:465-472. Expression of exogenous gene in the rhesus monkey is confined to the eye with combined use of ocular-specific gene promoter and PIL gene transfer technology.
36. ZHANG Y, BOADO RJ, PARDRIDGE WM: Marked enhancement in gene expression by targeting the human insulin receptor. J. Gene Med. (2003) 5(2):157-163.
37. KUAN CT, WIKSTRAND CJ, BIGNER DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer (2001) 8(2):83-96.
38. NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37(Suppl. 4):S9-S15.
39. SNUDDEN DK, SMITH PR, LAI D, NG MH, GRIFFIN BE: Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene (1995) 10(8):1545-1552.
40. ABE T, TERADA K, WAKIMOTO H et al.: PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. (2003) 63(9):2300-2305.
41. HEIMBERGER AB, LEARN CA, ARCHER GE et al.: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. (2002) 8(11):3496-3502.
42. LAL A, GLAZER CA, MARTINSON HM et al.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. (2002) 62(12):3335-3339.
43. COLOMA MJ, LEE HJ, KURIHARA A et al.: Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. (2000) 17(3):266-274. A genetically engineered chimeric mAb is transported across the primate BBB with the same activity as the original murine mAb.
44. ZHANG YF, BOADO RJ, PARDRIDGE WM: Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm. Res. (2003) 20(11):1779-1785.